All In Biotech

Drug Trial Radar · NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.

Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,122

Actual

Start

Aug 2008

Primary completion

Dec 2010

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment. The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • linagliptine 5 mgDrug

    safety and efficacy of linagliptine 5 mg open label

  • linagliptine 5 mg and pioglitazone 30 mgDrug

    efficacy and safety of the combination linagliptine and pioglitazone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Patients With Adverse Events (AEs)Time frame: 78 weeks
  2. Frequency of Patients With Investigator-defined Hypoglycaemic Adverse EventsTime frame: 78 weeks
  3. Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ)Time frame: 78 weeks
  4. Frequency of Patients With Adjudication of Cardiac and Cerebrovascular EventsTime frame: 78 weeks
  5. Number of Patients With Abnormalities in Vital SignsTime frame: 78 weeks
  6. Number of Patients With Abnormalities in Haematology: EosinophilsTime frame: 78 weeks
  7. Number of Patients With Abnormalities in Haematology: HaemoglobinTime frame: 78 weeks
  8. Number of Patients With Abnormalities in Haematology: HaematocritTime frame: 78 weeks
  9. Number of Patients With Abnormalities in Haematology: Red Blood Cell CountTime frame: 78 weeks
  10. Number of Patients With Abnormalities in Haematology: White Blood Cell CountTime frame: 78 weeks
  11. Number of Patients With Abnormalities in Haematology: PlateletsTime frame: 78 weeks
  12. Number of Patients With Abnormalities in Clinical Chemistry: PotassiumTime frame: 78 weeks
  13. Number of Patients With Abnormalities in Clinical Chemistry: Uric AcidTime frame: 78 weeks
  14. Number of Patients With Abnormalities in Clinical Chemistry: TriglyceridesTime frame: 78 weeks
  15. Number of Patients With Abnormalities in Clinical Chemistry: AmylaseTime frame: 78 weeks
  16. Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT)Time frame: 78 weeks
  17. Number of Patients With Abnormalities in Clinical Chemistry: CreatinineTime frame: 78 weeks
  18. Number of Patients With Abnormalities in Clinical Chemistry: Creatinine KinaseTime frame: 78 weeks
  19. Number of Patients With Abnormalities in Clinical Chemistry: PhosphateTime frame: 78 weeks
  20. Number of Patients With Abnormalities in Clinical Chemistry: CalciumTime frame: 78 weeks
  21. Number of Patients With Abnormalities in Clinical Chemistry: SodiumTime frame: 78 weeks
  22. Number of Patients With Abnormalities in Clinical Chemistry: Alanine Transaminase (ALT)Time frame: 78 weeks
  23. Number of Patients With Abnormalities in Clinical Chemistry: Aspartate Transaminase (AST)Time frame: 78 weeks
  24. Number of Patients With Abnormalities in Clinical Chemistry: GlucoseTime frame: 78 weeks
  25. Number of Patients With Abnormalities in Clinical Chemistry: BilirubinTime frame: 78 weeks
  26. Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP)Time frame: 78 weeks
  27. Number of Patients With Abnormalities in Clinical Chemistry: AlbuminTime frame: 78 weeks
  28. Number of Patients With Abnormalities in Clinical Chemistry: Lactate Dehydrogenase (LDH)Time frame: 78 weeks
  29. Number of Patients With Abnormalities in Clinical Chemistry: CholesterolTime frame: 78 weeks

Locations

232 sites in 32 countries. Site status is shown where the registry gives one.

  • 1218.40.10003 Boehringer Ingelheim Investigational Site

    Chula Vista, California

  • 1218.40.10014 Boehringer Ingelheim Investigational Site

    Spring Valley, California

  • 1218.40.10001 Boehringer Ingelheim Investigational Site

    Walnut Creek, California

  • 1218.40.10021 Boehringer Ingelheim Investigational Site

    Northglenn, Colorado

  • 1218.40.10010 Boehringer Ingelheim Investigational Site

    Hollywood, Florida

  • 1218.40.10011 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1218.40.10016 Boehringer Ingelheim Investigational Site

    Eugene, Oregon

  • 1218.40.10002 Boehringer Ingelheim Investigational Site

    Greer, South Carolina

  • 1218.40.10004 Boehringer Ingelheim Investigational Site

    Simpsonville, South Carolina

  • 1218.40.10005 Boehringer Ingelheim Investigational Site

    Dallas, Texas

  • 1218.40.10018 Boehringer Ingelheim Investigational Site

    Houston, Texas

  • 1218.40.10007 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 1218.40.10009 Boehringer Ingelheim Investigational Site

    Federal Way, Washington

  • 1218.40.54002 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.40.54010 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1218.40.54011 Boehringer Ingelheim Investigational Site

    Mendoza, Argentina

  • 1218.40.54015 Boehringer Ingelheim Investigational Site

    Parque Velez Sarfield, Argentina

  • 1218.40.43001 Boehringer Ingelheim Investigational Site

    Graz, Austria

  • 1218.40.43005 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1218.40.32005 Boehringer Ingelheim Investigational Site

    Bruges, Belgium

  • 1218.40.32007 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1218.40.32006 Boehringer Ingelheim Investigational Site

    Edegem, Belgium

  • 1218.40.32004 Boehringer Ingelheim Investigational Site

    Genk, Belgium

  • 1218.40.32003 Boehringer Ingelheim Investigational Site

    Ghent, Belgium

  • 1218.40.32002 Boehringer Ingelheim Investigational Site

    Huy, Belgium

  • 1218.40.32001 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1218.40.01005 Boehringer Ingelheim Investigational Site

    Calgary, Alberta, Canada

  • 1218.40.01010 Boehringer Ingelheim Investigational Site

    Calgary, Alberta, Canada

  • 1218.40.01003 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1218.40.01011 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1218.40.01006 Boehringer Ingelheim Investigational Site

    Etobicoke, Ontario, Canada

  • 1218.40.01009 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario, Canada

  • 1218.40.01002 Boehringer Ingelheim Investigational Site

    London, Ontario, Canada

  • 1218.40.01012 Boehringer Ingelheim Investigational Site

    Oakville, Ontario, Canada

  • 1218.40.01008 Boehringer Ingelheim Investigational Site

    Sarnia, Ontario, Canada

  • 1218.40.20005 Boehringer Ingelheim Investigational Site

    Strathroy, Ontario, Canada

  • 1218.40.01001 Boehringer Ingelheim Investigational Site

    Toronto, Ontario, Canada

  • 1218.40.01004 Boehringer Ingelheim Investigational Site

    Montague, Prince Edward Island, Canada

  • 1218.40.01007 Boehringer Ingelheim Investigational Site

    Saskatoon, Saskatchewan, Canada

  • 1218.40.86001 Boehringer Ingelheim Investigational Site

    Beijing, China

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.